Although we did not compare inter-group difference statistically because the follow-up period is too short for prostate cancer, BCR-free survival rates in cases with and without pSM were demonstrated as being 37.5% and 89.1% of those that were estimated at 2 years to achieve BCR-free survival, respectively (Figure1). This evidence concerns the gene BCR and Familial prostate cancer.